Company: PTHS
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001753926-25-001326
Chunk: 135

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 135
---
2,200,133

    $
    1,997,435

    $
    202,698

    10
    %

    Research and development

    709,112

    479,561

    229,551

    48
    %

    Professional fees

    2,155,155

    1,221,072

    934,083

    76
    %

    Total operating expenses

    5,064,400

    3,698,068

    1,366,332

    37
    %

    Loss from operations

    (5,064,400
    )

    (3,698,068
    )

    (1,366,332
    ) 

    (37
    )%

    Other expense

    (352,150
    )

    (635,881
    )

    283,731

    45
    %

    Net loss before provision for income taxes

    (5,416,550
    )

    (4,333,949
    )

    (1,082,601
    ) 

    (25
    )%

    Provision for income taxes

    —

    —

    —

    NA

    Net loss
     
    $
    (5,416,550
    )

    (4,333,949
    )

    (1,082,601
    ) 

    (25
    )%

37 

Operating
Expenses

Our
operating expenses consist of general and administrative expenses, research and development expenses and professional fees.

General
and Administrative Expenses

We
incurred general and administrative expenses for the six months ended June 30, 2025 and 2024 of $2,200,133 and $1,997,435, respectively.
For the six months ended June 30, 2025, compared to the same period in 2024, this represented an increase of $202,698, or 10%,
primarily as a result of increases of $138,396 in compensation expenses and an increase of $176,287 in stock compensation.

Research
and Development Expenses

We
incurred research and development expenses for the six months ended June 30, 2025 and 2024 of $709,112, and $479,561, respectively.
For the six months ended June 30, 2025, compared to the